beta
Trial Radar AI
Clinical Trial NCT07493590 (CAPTURE-HFpEF) for Heart Failure With Preserved Ejection Fraction (HFPEF) is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction 30,000 Biomarker-Driven Observational

Not yet recruiting
Clinical Trial NCT07493590 (CAPTURE-HFpEF) is an observational study for Heart Failure With Preserved Ejection Fraction (HFPEF) and is currently not yet recruiting. Enrollment is planned to begin on 1 April 2026 and continue until the study accrues 30,000 participants. Led by Herlev and Gentofte Hospital, this study is expected to complete by 1 April 2035. The latest data from ClinicalTrials.gov was last updated on 25 March 2026.
Brief Summary
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions.

The main questions to answer are:

Can systematic cardiovascular screening and deep phenotyping improve early identification and classification of HFpEF?

Which cli...

Show More
Detailed Description
Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that will benefit from early diagnosis, extensive diagnostic work-up, and individualized therapy. HF is a global health problem and one of the leading causes of cardiovascular (CV) morbidity and mortality. While many pharmacological and interventional treatments have been developed for HF with reduced ejection fraction (HFrEF), th...Show More
Official Title

CAPTURE-HFpEF (Cardiovascular Assessment and Phenotyping for Timely Understanding and Recognition of Evolving Heart Failure With Preserved Ejection Fraction)

Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Other Study IDs
  • CAPTURE-HFpEF
  • H-25050340
NCT ID Number
NCT07493590
Start Date (Actual)
2026-04-01
Last Update Posted
2026-03-25
Completion Date (Estimated)
2035-04-01
Enrollment (Estimated)
30,000
Study Type
Observational
Status
Not yet recruiting
Keywords
Heart failure
Heart Failure with Preserved Ejection Fraction (HFpEF)
Cardiovascular Mortality
Cardiovascular Disease
Chronic Heart Failure
Arms / Interventions
Participant Group/ArmIntervention/Treatment
N/A
HFpEF Observational Measurements
Observational measurements including collection of blood for biomarker and genetic analyses, echocardiography, ECG, and extraction of clinical data from electronic health records (comorbidities, medications, and prior hospitalizations). No treatment or procedure is assigned; all data reflect routine care and participant characteristics.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Early identification of HFpEF
Proportion (%) of individuals identified through the screening procedures outlined in the protocol among the target population.
baseline, pre-intervention
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Response, acceptance, and attendance rates
The proportion (%) of invited individuals who respond to the study invitation (response rate), the proportion (%) of responders who agree to participate (acceptance rate), and the proportion (%) of participants who attend the scheduled study visit (attendance rate).
Up to 24 months
Barriers to participation
Reported reasons for non-participation categorized and presented as percentages among individuals declining participation.
Up to 24 months
Patterns among non-responders
Distribution of non-responders based on educational attainment, household income, and geographic distance to the study site as indicators of socioeconomic and sociodemographic status, presented as percentages.
Up to 24 months
Prevalence of Heart failure with preserved ejection fraction in risk factor subgroups
Prevalence (%) of HFpEF among predefined risk factor subgroups, including individuals with diabetes, hypertension, and chronic kidney disease.
Up to 24 months
Feasibility of the logistical screening setup
Assessment of the logistical setup required to continuously examine individuals at risk for HFpEF within the study framework.
Up to 24 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Patients >60 years with ≥1 risk factor, OR
  • Patients >50 years with ≥2 risk factors
  • Hypertension
  • Type 1 or 2 diabetes
  • Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
  • Previous cardiotoxic drug exposure
  • atrial fibrillation
  • Ischemic heart disease
  • Previous heart valve surgery/intervention
  • Body mass index >30 kg/m² (self-reported)
  • Use of ≥40 mg furosemide
  • Obstructive sleep apnea
  • Non-alcoholic fatty liver disease

  • Cancer <1 year
  • Dialysis
  • COPD and O2
  • Nursing home
  • Age >90 years
  • Dementia
  • Known dilated cardiomyopathy
  • Prior organ-transplantation
  • Amyloidosis
Herlev and Gentofte Hospital logoHerlev and Gentofte Hospital
Study Responsible Party
Emil Wolsk, Principal Investigator, Specialist Cardiologist, Herlev and Gentofte Hospital
No contact data.
1 Study Locations in 1 Countries
Herlev and Gentofte Hospital, Copenhagen, Denmark
Emil Wolsk, MD, PhD, Contact, 38683868, [email protected]